Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Investor Relations Documents

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) investor relations documents from the company's IR site: 19 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-30Press releaseContineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
2026-06-30Press releaseContineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal
2026-06-01Press releaseContineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
2026-05-15Press releaseContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-12Press releaseContineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
2026-05-11Press releaseContineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conferen
2026-05-05Press releaseContineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
2026-05-01Press releaseContineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-30Press releaseContineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
2026-03-13Press releaseContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press releaseContineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
2026-03-03Press releaseContineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Press releaseContineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Press releaseContineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
Press releaseContineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
2025-03-06Press releaseContineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
2024-11-06Press releaseContineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
2024-08-13Press releaseContineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
2024-05-16Press releaseContineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

CTNM overview · CTNM earnings · CTNM financials · CTNM KPIs · CTNM ownership · CTNM peers · CTNM filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.